Opioid dependence is an increasing clinical and public health problem. Current pharmacotherapies have limited efficacy and cause serious side effects. Increasing bodies of evidences suggest the neuropeptide, oxytocin (OT), as a potential treatment for drug abuse disorders. The current study was designed to evaluate the effect of OT on withdrawal, craving and anxiety scores, cortisol and dehydroepiandrosterone sulphate (DHEAS) blood level in heroin-dependent male patients. This randomized, double-blind placebo-controlled clinical trial was conducted on 58 males with opioid dependence by Abstinence Center of Addictive People in Iran. The participants were randomly allocated to receive intranasal OT (single dose; 40 IU, n = 29) or placebo (n = 29). Heroine withdrawal, craving and anxiety scores were measured using the Opioid Withdrawal Scale, Visual Analogue Scale and (Desire for Drug Questionnaire), and Hamilton checklist respectively. The cortisol and DHEAS levels at baseline and different post-intervention time were measured using a competitive immunoanalysis method. Acute OT administration reduced craving and withdrawal scores but did not change anxiety significantly. Single dose of OT decreased the level of cortisol and improved the cortisol/DHEAS ratio in the heroin users during abstinence (p < 0.01). These results suggest that OT may be useful in the attenuation of craving, withdrawal symptom in heroin-dependent patients and might be considered a new potential treatment for heroin dependence where positive effects of OT on stress-related hormones may be involved in this effect of OT.

1.
United Nations: Office of Drug and Crime: World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9).
2.
Yen CF, Lin HC, Wang PW, Ko CH, Lee KH, Hsu CY, Chung KS, Wu HC, Cheng CP: Heroin craving and its correlations with clinical outcome indicators in people with heroin dependence receiving methadone maintenance treatment. Compr Psychiatry 2016; 65: 50–56.
3.
Colom Farran J, Casas M, Pérez de Los Cobos J, Del Río M, Roncero C, Castells X, Valero S, Eiroa-Orosa FJ, Batlle F, Trujols J: Feasibility of double-blind clinical trials with oral diacetylmorphine: a randomized controlled phase II study in an inpatient setting. Eur Addict Res 2012; 18: 279–287.
4.
Krantz MJ, Rowan SB, Schmittner J, Bucher Bartelson B: Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007; 26: 79–85.
5.
Singh F, Nunag J, Muldoon G, Cadenhead KS, Pineda JA, Feifel D: Effects of intranasal oxytocin on neural processing within a socially relevant neural circuit. Eur Neuropsychopharmacol 2016; 26: 626–630.
6.
Amini-Khoei H, Amiri S, Mohammadi-Asl A, Alijanpour S, Poursaman S, Haj-Mirzaian A, Rastegar M, Mesdaghinia A, Banafshe HR, Sadeghi E, Samiei E, Mehr SE, Dehpour AR: Experiencing neonatal maternal separation increased pain sensitivity in adult male mice: involvement of oxytocinergic system. Neuropeptides 2017; 61: 77–85.
7.
Lee MR, Rohn MC, Tanda G, Leggio L: Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. CNS Drugs 2016; 30: 109–123.
8.
Kovács GL, Sarnyai Z, Szabó G, Telegdy G: Development of morphine tolerance under tonic control of brain oxytocin. Drug Alcohol Depend 1986; 17: 369–375.
9.
McRae-Clark AL, Baker NL, Maria MM, Brady KT: Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology (Berl) 2013; 228: 623–631.
10.
Lin SH, Lee LT, Tsai HC, Chen KC, Chen WT, Lee IH, Lu RB, Chen PS, Yang YK: Association between blood level of plasma oxytocin and novelty seeking among methadone-maintained heroin users. Neuropsychobiology 2015; 71: 65–69.
11.
Light KC, Grewen KM, Amico JA, Boccia M, Brownley KA, Johns JM: Deficits in plasma oxytocin responses and increased negative affect, stress, and blood pressure in mothers with cocaine exposure during pregnancy. Addict Behav 2004; 29: 1541–1564.
12.
Walter M, Bentz D, Schicktanz N, Milnik A, Aerni A, Gerhards C, Schwegler K, Vogel M, Blum J, Schmid O, Roozendaal B, Lang UE, Borgwardt S, de Quervain D: Effects of cortisol administration on craving in heroin addicts. Transl Psychiatry 2015; 5:e610.
13.
Schmidt A, Borgwardt S, Gerber H, Wiesbeck GA, Schmid O, Riecher-Rössler A, Smieskova R, Lang UE, Walter M: Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses. Biol Psychiatry 2014; 76: 289–296.
14.
Olff M, de Vries GJ, Güzelcan Y, Assies J, Gersons BP: Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinology 2007; 32: 619–626.
15.
Rasmusson AM, Vasek J, Lipschitz DS, Vojvoda D, Mustone ME, Shi Q, Gudmundsen G, Morgan CA, Wolfe J, Charney DS: An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. Neuropsychopharmacology 2004; 29: 1546–1557.
16.
Lee MR, Weerts EM: Oxytocin for the treatment of drug and alcohol use disorders. Behav Pharmacol 2016; 27: 640–648.
17.
Ghaderi A, Banafshe HR, Motmaen M, Rasouli-Azad M, Bahmani F, Asemi Z: Clinical trial of the effects of vitamin D supplementation on psychological symptoms and metabolic profiles in maintenance methadone treatment patients. Prog Neuropsychopharmacol Biol Psychiatry 2017; 79(pt B): 84–89.
18.
Wesson DR, Ling W: The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003; 35: 253–259.
19.
Wewers ME, Lowe NK: A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990; 13: 227–236.
20.
Franken IH, Hendriksa VM, van den Brink W: Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav 2002; 27: 675–685.
21.
Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55.
22.
Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M: Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 2009; 65: 728–731.
23.
Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U: Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003; 54: 1389–1398.
24.
Ekhtiari H, Edalati H, Behzadi A, Safaea H, Noori M, Mokri A: Construction and evaluation of the effectiveness of five visual tests of assessment of substance craving in addicts, Iran. J Psychiatry Clin Psycho 2008; 14: 337–349.
25.
Yu J, Zhang S, Epstein DH, Fang Y, Shi J, Qin H, Yao S, Le Foll B, Lu L: Gender and stimulus difference in cue-induced responses in abstinent heroin users. Pharmacol Biochem Behav 2007; 86: 485–492.
26.
Kovács GL, Sarnyai Z, Szabó G: Oxytocin and addiction: a review. Psychoneuroendocrinology 1998; 23: 945–962.
27.
You ZD, Li JH, Song CY, Wang CH, Lu CL: Chronic morphine treatment inhibits oxytocin synthesis in rats. Neuroreport 2000; 11: 3113–3116.
28.
Zanos P, Georgiou P, Wright SR, Hourani SM, Kitchen I, Winsky-Sommerer R, Bailey A: The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice. Neuropsychopharmacology 2014; 39: 855–865.
29.
Buisman-Pijlman FT, Sumracki NM, Gordon JJ, Hull PR, Carter CS, Tops M: Individual differences underlying susceptibility to addiction: role for the endogenous oxytocin system. Pharmacol Biochem Behav 2014; 119: 22–38.
30.
Liu Y, Young KA, Curtis JT, Aragona BJ, Wang Z: Social bonding decreases the rewarding properties of amphetamine through a dopamine D1 receptor-mediated mechanism. J Neurosci 2011; 31: 7960–7966.
31.
Young LJ, Rainnie DG, et al: Neuroanatomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis of the rat: implications for balancing stress and affect. Psychoneuroendocrinology 2011; 36: 1312–1326.
32.
Tops M, Koole SL, IJzerman H, Buisman-Pijlman FT: Why social attachment and oxytocin protect against addiction and stress: insights from the dynamics between ventral and dorsal corticostriatal systems. Pharmacol Biochem Behav 2014; 119: 39–48.
33.
Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M: Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 2009; 65: 728–731.
34.
Burkett JP, Young LJ: The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction. Psychopharmacology (Berl) 2012; 224: 1–26.
35.
Di Simplicio M, Massey-Chase R, Cowen PJ, Harmer CJ: Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol 2009; 23: 241–248.
36.
Jurek B, Slattery DA, Hiraoka Y, Liu Y, Nishimori K, Aguilera G, Neumann ID, van den Burg EH: Oxytocin regulates stress-induced Crf gene transcription through CREB-regulated transcription coactivator 3. J Neurosci 2015; 35: 12248–12260.
37.
Vaccari C, Lolait SJ, Ostrowski NL: Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 1998; 139: 5015–5033.
38.
Baracz SJ, Everett NA, McGregor IS, Cornish JL: Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine-seeking behaviour in rats. Addict Biol 2016; 21: 316–325.
39.
Qi J, Yang JY, Wang F, Zhao YN, Song M, Wu CF: Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement. Neuropharmacology 2009; 56: 856–865.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.